Oxygen Atomizing Inhalation of EGCG in the Treatment COVID-19 Pneumonia in Cancer Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide
variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous,
and metabolic effects via modulation of a variety of intracellular signaling cascades. In
addition, preclinical studies have also emphasized the antiviral activity of
epigallocatechin-3-gallate (EGCG), including SARS-CoV-2.
In previous studies, we found that EGCG can prevent and cure radiation-induced normal tissue
damage in tumor patients. In clinical studies, we found that EGCG can prevent and treat
radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation
oral mucositis with high safety. Thus, we designed this phase I-II clinical study in order to
investigate the possible role of EGCG in tumor patients infected with SARS-CoV-2.